Wechselwirkungen · Orladeyo
Orladeyo 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-144591 · Präparat HOS-099216
CYP2D6 substrates Berotralstat is a moderate inhibitor of CYP2D6, increasing the Cmax and AUC of dextromethorphan by 196% and 177%, respectively, and the Cmax and AUC of desipramine by 64% and 87%, respectively. Concomitant administration may increase exposure of other medicinal products that are CYP2D6 substrates. Refer to the SmPC for concomitant medicinal products that are predominantly metabolised by CYP2D6, particularly those with a narrow therapeutic index (e.g. thioridazine, pimozide) or whose prescribing information recommends therapeutic monitoring (e.g. tricyclic antidepressants). Dose adjustments of these medicinal products may be required (see section 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): desipramine (HOS-086249) thioridazine (HOS-086281) pimozide (HOS-085600) dextromethorphan (HOS-109265)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-06T11:50:00Z · SHA-256 677e4228648fad20ff699c4fdde1afae259098b3f1b5cce5f019599df82214db · Passage 2d04075894a6f693d4388e256deebe239f1cc8a7a08008a0bee251e14c618c32 · Zeichen 1403–2080 im Abschnitt